drugset / Trial / NCT03159455

This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated

NCT03159455

Phase 1 Completed 48 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of the current study is to investigate the safety and tolerability of BI 1467335 in healthy Japanese male subjects following oral administration of multiple rising doses The Caucasian group will receive higher dose only. A secondary objective is the exploration of the pharmacokinetics and pharmacodynamics of BI 1467335 in healthy Japanese and Caucasian male subjects.

Timeline

Start
2017-06-07
Primary completion
2017-12-16
Completion
2017-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1467335 Unknown Oral

Indications

No indication recorded.